中文About 18 million people worldwide are diagnosed with malignant tumors every year, with 10 million of patients of this illness succumbed to fatality of this deadly disease. Scientists and researchers are working diligently in search for effective therapy for cancers so as to bring better quality care to those who are in need. Unfortunately, despite such effort, conquering cancers remain an insurmountable task even today. Unogen is a biotech company focuses on cancers and we strive to employ world-class scientific technology and clinical expertise to develop the best cancer therapy for patients. We also adopt the most advanced AI and web-based technology to promote our novel therapy to patients all over the world.
WE ARE UNOGEN
ABOUT US
First Rated Technology and Our Utmost Efforts
“To spend life side by side, in the sway of our dreams: your patriotic dream, our humanitarian dream and our scientific dream”
– Madame Curie
OUR VALUES
Our principle of operation is integrity as well as pursue our R&D work based on novel sciences. We believe success of any biopharma company must be based on creating value to address the unmet medical need. Our value proposition is always about providing the best therapy to our patients to improve their quality of life and overall well-beings.
OUR MISSION
Focus on Oncology & Develop the Best Cancer Therapy for Patients
WHOLE PROCESS FLAWLESS DEVELOPMENT
OUR SCIENCE
World-first drug or best drug asset
Focus on lung cancer, breast cancer, pancreatic cancer and liver cancer with relatively large patient populations
The best asset balance of biologics and small molecule chemical drugs
Questions and Cooperations
You are welcome to contact us if you have any questions or requirements in the fields of science, technology, business cooperation, investment or human resources.
UNOGENBIO MADE GOOD DRUGS
OUR PIPELINE
We will balance our assets between big molecular antibody drugs and small molecular chemical drugs, and launch various kinds of drugs for adult tumors and children tumors.
EXECUTES TEAM
Before founding UnogenBio，Ms. Fiona Yu has over 20 years of corporate executive experience. She focuses on pharmaceutical strategy research and has accumulated extensive experience in the biopharmaceutical field in both China and the United States. Ms. Yu has written a series of strategic analysis articles about multinational pharmaceutical giants, which are generally considered to be of great reference and thinking value by senior people in the industry.
Fiona YuCEO
Dr. Anderson leads Unogen’s science strategy and its execution with our biopharma collaboration partners. He is an oncology R&D leader with over 25 years of experience in the biotechnology and pharmaceutical industry, successfully initiating projects, developing agents utilizing novel and complex platforms, leading discovery and cross-functional compound development teams, and setting overall discovery and development strategy. He led teams that have taken multiple antibody based anti-cancer therapeutics to the NME stage, with several progressing to IND and clinical evaluation.
Mark AndersonCIO
President of Qilu Pharmaceutical Company, oversaw the clinical research and development of Qilu's clinical innovative drugs and biosimilar drugs. Before he joined Qilu, he was Vice President of Clinical Oncology of Hengrui USA. He previously served as the Global Medical Unit Head for Breast Cancer at Novartis Oncology. He also served as Senior Medical Director of Celgene Corporation and US Medical Director of Bayer Pharmaceuticals. He has over 28 years of experience in the pharmaceutical industry in clinical development and medical fields in various disease or therapeutic areas prior to oncology, autoimmune and infectious diseases.
Oliver KongCMO
Prior to joining UnogenBio, Dr. Cheung has more than 25 years’ leadership role experience in biologics drug development, from the discovery research to proof-of-concept clinical stage. He served as senior executive position in multiple big pharma and biotech companies such as Johnson & Johnson, Adagene, Compugen, Biomed Valley Discovery, and Xencor. Dr. Cheung has led the successful filing of many INDs and was a key participant in the US approval of multiple BLAs. He is a pharmacologist, and was a postdoctoral fellow at MD Anderson Cancer Research Center.
Peter CheungCSO
Dr. Lo is an experienced drug discovery and development leader, with over 20 years of industry pharmaceuticals experience in the USA and overseas. Including more than 10 years with Boehringer Ingelheim in Connecticut, 2 years with KBP Biosciences in Jinan, China and was the founder of Synovel Laboratory in Connecticut. Prior to joining Unogen, he was the chief operating officer of QX Therapeutics Inc in Connecticut and during his tenure, he had successfully led to 2 FDA IND in the US. He is knowledgeable and liaises with the US FDA and the IND process. He has a track record on advancing drug candidates to clinical trials in the US.He has published more than 19 peer review papers and is the inventor of 25 patents. Dr. Lo obtained his Ph.D. degree in The Chinese University of Hong Kong and Post-doctorate Fellow at Ohio State University.
Ho Yin Lo, Ph.D.Senior Vice President of Medicinal Chemistry
We would love to know you
GET IN TOUCH WITH US
